{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,29]],"date-time":"2026-08-29T14:14:44Z","timestamp":1788012884575,"version":"build-2784847793"},"reference-count":35,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2026,2,1]],"date-time":"2026-02-01T00:00:00Z","timestamp":1769904000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,2,1]],"date-time":"2026-02-01T00:00:00Z","timestamp":1769904000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","journal.chestnet.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["CHEST"],"published-print":{"date-parts":[[2026,2]]},"DOI":"10.1016\/j.chest.2025.09.009","type":"journal-article","created":{"date-parts":[[2025,9,18]],"date-time":"2025-09-18T15:45:43Z","timestamp":1758210343000},"page":"428-439","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":5,"title":["Comparative Effectiveness of Tocilizumab vs Rituximab in Rheumatoid Arthritis-Associated Interstitial Lung Disease"],"prefix":"10.1016","volume":"169","author":[{"given":"Zewen","family":"Wu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4152-9296","authenticated-orcid":false,"given":"Po-Cheng","family":"Shih","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shiow-Ing","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gema Hern\u00e1ndez","family":"Ibarburu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qing-Wen","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"James Cheng Chung","family":"Wei","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Liyun","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"10","key":"10.1016\/j.chest.2025.09.009_bib1","doi-asserted-by":"crossref","first-page":"1899","DOI":"10.1111\/1756-185X.14830","article-title":"Navigating the maze of treatment strategies for RA-ILD: insights and innovations for better patient outcomes","volume":"26","author":"Shih","year":"2023","journal-title":"Int J Rheum Dis"},{"issue":"1","key":"10.1016\/j.chest.2025.09.009_bib2","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1186\/s13075-024-03362-1","article-title":"Risk factors of mortality in patients with rheumatoid arthritis-associated interstitial lung disease: a single-centre prospective cohort study","volume":"26","author":"Song","year":"2024","journal-title":"Arthritis Res Ther"},{"issue":"8","key":"10.1016\/j.chest.2025.09.009_bib3","doi-asserted-by":"crossref","first-page":"1182","DOI":"10.1002\/art.42861","article-title":"2023 American College of Rheumatology (ACR)\/American College of Chest Physicians (CHEST) guideline for the treatment of interstitial lung disease in people with systemic autoimmune rheumatic diseases","volume":"76","author":"Johnson","year":"2024","journal-title":"Arthritis Rheumatol"},{"key":"10.1016\/j.chest.2025.09.009_bib4","article-title":"Biological mechanisms of pulmonary inflammation and its association with seropositive rheumatoid arthritis","volume":"16","author":"Yang","year":"2025","journal-title":"Front Immunol"},{"issue":"10","key":"10.1016\/j.chest.2025.09.009_bib5","doi-asserted-by":"crossref","first-page":"581","DOI":"10.1038\/s41584-019-0275-x","article-title":"Mechanisms of lung disease development in rheumatoid arthritis","volume":"15","author":"Wang","year":"2019","journal-title":"Nature Rev Rheumatol"},{"issue":"7","key":"10.1016\/j.chest.2025.09.009_bib6","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0022667","article-title":"Interleukin-6 contributes to inflammation and remodeling in a model of adenosine mediated lung injury","volume":"6","author":"Pedroza","year":"2011","journal-title":"PloS One"},{"issue":"12","key":"10.1016\/j.chest.2025.09.009_bib7","doi-asserted-by":"crossref","first-page":"6460","DOI":"10.3390\/ijms25126460","article-title":"The lung in rheumatoid arthritis\u2014friend or enemy?","volume":"25","author":"Anton","year":"2024","journal-title":"Int J Molecular Sci"},{"issue":"7","key":"10.1016\/j.chest.2025.09.009_bib8","doi-asserted-by":"crossref","first-page":"2601","DOI":"10.1007\/s10067-025-07533-6","article-title":"Efficacy of rituximab versus cyclophosphamide in connective tissue disease-related interstitial lung disease: a systematic review and meta-analysis","volume":"44","author":"Liu","year":"2025","journal-title":"Clin Rheumatol"},{"issue":"1","key":"10.1016\/j.chest.2025.09.009_bib9","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1016\/S2213-2600(22)00359-9","article-title":"Rituximab versus intravenous cyclophosphamide in patients with connective tissue disease-associated interstitial lung disease in the UK (RECITAL): a double-blind, double-dummy, randomised, controlled, phase 2b trial","volume":"11","author":"Maher","year":"2023","journal-title":"Lancet Respir Med"},{"issue":"3","key":"10.1016\/j.chest.2025.09.009_bib10","doi-asserted-by":"crossref","first-page":"e166","DOI":"10.1016\/S2665-9913(24)00265-0","article-title":"Advanced therapies in US veterans with rheumatoid arthritis-associated interstitial lung disease: a retrospective, active-comparator, new-user, cohort study","volume":"7","author":"England","year":"2025","journal-title":"Lancet Rheumatol"},{"issue":"4","key":"10.1016\/j.chest.2025.09.009_bib11","doi-asserted-by":"crossref","first-page":"861","DOI":"10.1016\/j.chest.2022.11.035","article-title":"Treatment outcomes for rheumatoid arthritis-associated interstitial lung disease: a real-world, multisite study of the impact of immunosuppression on pulmonary function trajectory","volume":"163","author":"Matson","year":"2023","journal-title":"Chest"},{"issue":"2","key":"10.1016\/j.chest.2025.09.009_bib12","doi-asserted-by":"crossref","first-page":"317","DOI":"10.46497\/ArchRheumatol.2024.10199","article-title":"Rituximab for rheumatoid arthritis-related interstitial lung disease: a systematic review and meta-analysis","volume":"39","author":"Boppana","year":"2024","journal-title":"Arch Rheumatol"},{"issue":"9","key":"10.1016\/j.chest.2025.09.009_bib13","doi-asserted-by":"crossref","first-page":"1085","DOI":"10.1111\/imj.14670","article-title":"Tocilizumab therapy in rheumatoid arthritis with interstitial lung disease: a multicentre retrospective study","volume":"50","author":"Manfredi","year":"2020","journal-title":"Intern Med J"},{"key":"10.1016\/j.chest.2025.09.009_bib14","first-page":"127","article-title":"Safety of tocilizumab on rheumatoid arthritis in patients with interstitial lung disease","volume":"16","author":"Otsuji","year":"2024","journal-title":"Open Access Rheumatol Res Rev"},{"issue":"4","key":"10.1016\/j.chest.2025.09.009_bib15","doi-asserted-by":"crossref","first-page":"874","DOI":"10.3390\/jcm10040874","article-title":"Predictors of progression and mortality in patients with prevalent rheumatoid arthritis and interstitial lung disease: a prospective cohort study","volume":"10","author":"Mena-V\u00e1zquez","year":"2021","journal-title":"J Clin Med"},{"key":"10.1016\/j.chest.2025.09.009_bib16","doi-asserted-by":"crossref","DOI":"10.3389\/fphar.2025.1516126","article-title":"A comprehensive review of methodologies and application to use the real-world data and analytics platform TriNetX","volume":"16","author":"Ludwig","year":"2025","journal-title":"Front Pharmacol"},{"issue":"3","key":"10.1016\/j.chest.2025.09.009_bib17","doi-asserted-by":"crossref","DOI":"10.1136\/rmdopen-2023-003038","article-title":"COVID-19 outcomes in patients with rheumatoid arthritis with biologic or targeted synthetic DMARDs","volume":"9","author":"Tsai","year":"2023","journal-title":"RMD Open"},{"key":"10.1016\/j.chest.2025.09.009_bib18","article-title":"A chronological review of COVID-19 case fatality rate and its secular trend and investigation of all-cause mortality and hospitalization during the Delta and Omicron waves in the United States: a retrospective cohort study","volume":"11","author":"Li","year":"2023","journal-title":"Front Public Health"},{"issue":"1","key":"10.1016\/j.chest.2025.09.009_bib19","doi-asserted-by":"crossref","first-page":"186","DOI":"10.1007\/s10238-024-01448-3","article-title":"Abatacept versus tumor necrosis factor inhibitors on mortality and medical utilizations in the treatment of rheumatoid arthritis associated interstitial lung disease: a large-scale real-world retrospective cohort study","volume":"24","author":"Shih","year":"2024","journal-title":"Clin Exp Med"},{"issue":"4","key":"10.1016\/j.chest.2025.09.009_bib20","doi-asserted-by":"crossref","DOI":"10.1111\/1756-185X.70203","article-title":"NHIRD and TriNetX in rheumatology: opportunities and challenges","volume":"28","author":"Cheng","year":"2025","journal-title":"Int J Rheum Dis"},{"issue":"21","key":"10.1016\/j.chest.2025.09.009_bib21","doi-asserted-by":"crossref","first-page":"1975","DOI":"10.1056\/NEJMp2407586","article-title":"\u201cTarget trial emulation\u201d for observational studies\u2014potential and pitfalls","volume":"391","author":"Hubbard","year":"2024","journal-title":"N Engl J Med"},{"key":"10.1016\/j.chest.2025.09.009_bib22","article-title":"Association of abatacept with lower mortality risk compared to rituximab in rheumatoid arthritis-associated interstitial lung disease: an emulated target trial","author":"Shih","year":"2025","journal-title":"Arthr Rheumatol"},{"issue":"8","key":"10.1016\/j.chest.2025.09.009_bib23","doi-asserted-by":"crossref","first-page":"758","DOI":"10.1093\/aje\/kwv254","article-title":"Using big data to emulate a target trial when a randomized trial is not available","volume":"183","author":"Hern\u00e1n","year":"2016","journal-title":"Am J Epidemiol"},{"issue":"8","key":"10.1016\/j.chest.2025.09.009_bib24","doi-asserted-by":"crossref","first-page":"1305","DOI":"10.1681\/ASN.0000000000000152","article-title":"Target trial emulation to improve causal inference from observational data: what, why, and how?","volume":"34","author":"Fu","year":"2023","journal-title":"J Am Soc Nephrol"},{"issue":"135","key":"10.1016\/j.chest.2025.09.009_bib35","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1183\/09059180.00008014","article-title":"Rheumatoid arthritis-associated lung disease","volume":"24","author":"Shaw","year":"2015","journal-title":"Eur Respir Rev"},{"issue":"10","key":"10.1016\/j.chest.2025.09.009_bib25","doi-asserted-by":"crossref","first-page":"1700","DOI":"10.1136\/annrheumdis-2017-211138","article-title":"A population-based cohort study of rheumatoid arthritis-associated interstitial lung disease: comorbidity and mortality","volume":"76","author":"Hyldgaard","year":"2017","journal-title":"Ann Rheumatic Dis"},{"key":"10.1016\/j.chest.2025.09.009_bib26","doi-asserted-by":"crossref","DOI":"10.1016\/j.semarthrit.2025.152735","article-title":"Non-TNFi biologic and targeted synthetic DMARDs in rheumatoid arthritis-associated interstitial lung disease: a propensity score-matched, active-comparator, new-user study","volume":"73","author":"Frideres","year":"2025","journal-title":"Semin Arthritis Rheum"},{"issue":"2","key":"10.1016\/j.chest.2025.09.009_bib27","doi-asserted-by":"crossref","DOI":"10.1136\/rmdopen-2023-003789","article-title":"Impact of DMARD treatment and systemic inflammation on all-cause mortality in patients with rheumatoid arthritis and interstitial lung disease: a cohort study from the German RABBIT register","volume":"10","author":"Rudi","year":"2024","journal-title":"RMD Open"},{"key":"10.1016\/j.chest.2025.09.009_bib28","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s12931-015-0261-z","article-title":"Bidirectional role of IL-6 signal in pathogenesis of lung fibrosis","volume":"16","author":"Kobayashi","year":"2015","journal-title":"Respir Res"},{"issue":"5","key":"10.1016\/j.chest.2025.09.009_bib29","doi-asserted-by":"crossref","first-page":"972","DOI":"10.3109\/s10165-012-0780-0","article-title":"Clinical characteristics of influenza virus infection in juvenile idiopathic arthritis patients treated with tocilizumab","volume":"23","author":"Kawada","year":"2013","journal-title":"Mod Rheumatol"},{"issue":"5","key":"10.1016\/j.chest.2025.09.009_bib30","doi-asserted-by":"crossref","first-page":"782","DOI":"10.1080\/14397595.2018.1515059","article-title":"Comparison of the clinical characteristics and severity of community-acquired pneumonia between patients with rheumatoid arthritis treated with tocilizumab and those treated with TNF inhibitor","volume":"29","author":"Nagai","year":"2019","journal-title":"Mod Rheumatol"},{"issue":"1","key":"10.1016\/j.chest.2025.09.009_bib31","doi-asserted-by":"crossref","DOI":"10.1136\/rmdopen-2023-003998","article-title":"Eosinopenia and routine inflammatory biomarkers are helpful for the diagnosis of infection in patients treated with IL-6 pathway antagonists","volume":"10","author":"Glatre","year":"2024","journal-title":"RMD Open"},{"issue":"7","key":"10.1016\/j.chest.2025.09.009_bib32","doi-asserted-by":"crossref","first-page":"795","DOI":"10.1111\/1756-185X.14351","article-title":"Predictors of progression in rheumatoid arthritis-associated interstitial lung disease: a single-center retrospective study from China","volume":"25","author":"Liu","year":"2022","journal-title":"Int J Rheumatic Dis"},{"key":"10.1016\/j.chest.2025.09.009_bib33","doi-asserted-by":"crossref","DOI":"10.3389\/fmed.2023.1265355","article-title":"Progression of radiographic fibrosis in rheumatoid arthritis-associated interstitial lung disease","volume":"10","author":"Chai","year":"2023","journal-title":"Front Med"},{"issue":"3","key":"10.1016\/j.chest.2025.09.009_bib34","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1111\/resp.14609","article-title":"Serum C-reactive protein is associated with earlier mortality across different interstitial lung diseases","volume":"29","author":"Stock","year":"2024","journal-title":"Respirology"}],"container-title":["CHEST"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0012369225052547?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0012369225052547?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,4,21]],"date-time":"2026-04-21T00:40:45Z","timestamp":1776732045000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0012369225052547"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,2]]},"references-count":35,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2026,2]]}},"alternative-id":["S0012369225052547"],"URL":"https:\/\/doi.org\/10.1016\/j.chest.2025.09.009","relation":{},"ISSN":["0012-3692"],"issn-type":[{"value":"0012-3692","type":"print"}],"subject":[],"published":{"date-parts":[[2026,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Comparative Effectiveness of Tocilizumab vs Rituximab in Rheumatoid Arthritis-Associated Interstitial Lung Disease","name":"articletitle","label":"Article Title"},{"value":"CHEST","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.chest.2025.09.009","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 American College of Chest Physicians. Published by Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}]}}